U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H14N6O2
Molecular Weight 346.3428
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TG-100115

SMILES

NC1=NC(N)=C2N=C(C3=CC=CC(O)=C3)C(=NC2=N1)C4=CC(O)=CC=C4

InChI

InChIKey=UJIAQDJKSXQLIT-UHFFFAOYSA-N
InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)

HIDE SMILES / InChI

Molecular Formula C18H14N6O2
Molecular Weight 346.3428
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

TG-100115 is a potent dual inhibitor of PI3K-gamma and PI3K-delta. TG-100115 has broad anti-inflammatory activities. TG-100115 provided potent cardioprotection, reducing infarct development and preserving myocardial function. In murine models of asthma and acute stages of chronic obstructive pulmonary disease, aerosolized TG100-115 demonstrated not only markedly inhibited anti-inflammatory activity but also, in the case of the asthma model, improved functional outcome for the test animals. TG-100115 can be used as a potent TRPM7 kinase inhibitor and a potent inhibitor of breast cancer cell migration.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 11.7704 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
2006 Dec 26
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Patents

Sample Use Guides

Rat: 0.5 mg/kg
Route of Administration: Intravenous
TG-100115 had no effects on endothelial cells proliferation even at relatively high concentrations (up to 10 uM). TG-100115 (10 uM) interrupts other VEGF signaling pathways, such as those that culminate in VE-cadherin phosphorylation.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:12:53 GMT 2023
Edited
by admin
on Sat Dec 16 09:12:53 GMT 2023
Record UNII
7ACH1U1E2M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TG-100115
Common Name English
TG-100-115
Code English
TG 100-115
Code English
PHENOL, 3,3'-(2,4-DIAMINO-6,7-PTERIDINEDIYL)BIS-
Systematic Name English
6,7-BIS(3-HYDROXYPHENYL)PTERIDINE-2,4-DIAMINE
Systematic Name English
Code System Code Type Description
PUBCHEM
10427712
Created by admin on Sat Dec 16 09:12:53 GMT 2023 , Edited by admin on Sat Dec 16 09:12:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID20218009
Created by admin on Sat Dec 16 09:12:53 GMT 2023 , Edited by admin on Sat Dec 16 09:12:53 GMT 2023
PRIMARY
CAS
677297-51-7
Created by admin on Sat Dec 16 09:12:53 GMT 2023 , Edited by admin on Sat Dec 16 09:12:53 GMT 2023
PRIMARY
FDA UNII
7ACH1U1E2M
Created by admin on Sat Dec 16 09:12:53 GMT 2023 , Edited by admin on Sat Dec 16 09:12:53 GMT 2023
PRIMARY
DRUG BANK
DB05552
Created by admin on Sat Dec 16 09:12:53 GMT 2023 , Edited by admin on Sat Dec 16 09:12:53 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY